Pleasanton, CA and Philadelphia, PA, Aug. 02, 2024 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and will commercialize bentracimab in the United States, announced today...

  PHILADELPHIA and SAN FRANCISCO, 11 May 2023: SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. Bentracimab is a novel, monoclonal antibody fragment designed to reverse...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Investigational New Drug (IND) application for bentracimab submitted to the Center for Drug Evaluation (CDE)...

EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at Week 26 Mean hemoglobin levels in the EMPAVELI group increased from 9.4...

EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are: Treatment naïve Switching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris® (ravulizumab) EMPAVELI was superior to Soliris for the change from baseline in hemoglobin...

Nektar to receive up to $150 million in development funding through a novel financing collaboration agreement.   SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing...

PLEASANTON, Calif., Oct. 27, 2020 /PRNewswire/ -- SFJ Pharmaceuticals® ("SFJ") is pleased to note that its partner Apellis Pharmaceuticals Inc. ("Apellis") (Waltham, MA) and Swedish Orphan Biovitrum AB ("Sobi™") (Stockholm, Sweden) today announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for...